Zenas BioPharma Files 8-K

Ticker: ZBIO · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1953926

Sentiment: neutral

Topics: disclosure, filing

TL;DR

Zenas BioPharma filed a routine 8-K. Nothing major to see here.

AI Summary

Zenas BioPharma, Inc. filed an 8-K on December 2, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates Zenas BioPharma is making standard disclosures to the SEC, which is routine for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any unusual or negative events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Zenas BioPharma, Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on December 2, 2024.

In which U.S. state is Zenas BioPharma, Inc. incorporated?

Zenas BioPharma, Inc. is incorporated in Delaware.

What is the Commission File Number for Zenas BioPharma, Inc.?

The Commission File Number for Zenas BioPharma, Inc. is 001-42270.

What is the business address of Zenas BioPharma, Inc.?

The business address of Zenas BioPharma, Inc. is 852 Winter Street, Suite 250, Waltham, MA 02451.

Filing Stats: 696 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2024-12-02 16:34:45

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Zenas BioPharma, Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation (the "Investor Presentation") which may be used, in whole or in part, and subject to modification, on December 2, 2024 and at subsequent meetings with investors or analysts. The Investor Presentation provides updated information on the Company's clinical trials, including the Company's fully-enrolled Phase 3 INDIGO trial of obexelimab in patients with IgG4-Related Disease and the expected timeline to report topline results, the currently-enrolling Phase 2 MoonStone trial of obexelimab in patients with Relapsing Multiple Sclerosis and the expected timeline to report the 12-week primary endpoint results, the currently-enrolling Phase 2 SunStone trial of obexelimab in patients with Systemic Lupus Erythematosus and the expected timeline to complete enrollment and report topline results and preliminary, interim data from the dose confirmation run-in period of the Phase 2 SApHiAre trial of obexelimab in patients with warm Autoimmune Hemolytic Anemia, as well as the status of the program. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements. The Investor Presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Investor Presentation regarding these forwar

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated December 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENAS BIOPHARMA, INC. By: /s/ Jennifer Fox Name: Jennifer Fox Title: Chief Business Officer and Chief Financial Officer Date: December 2, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing